<!doctype html><html lang=en-us><head><meta charset=utf-8><meta name=viewport content="width=device-width,initial-scale=1"><meta http-equiv=x-ua-compatible content="IE=edge"><meta name=generator content="Source Themes Academic 4.7.0"><meta name=author content="Janani Ravi"><meta name=description content="Tuberculosis (TB) remains the second leading cause of infectious disease mortality worldwide, killing over one million people annually. Rising antibiotic resistance has created an urgent need for host-directed therapeutics (HDTs) — preferably by repurposing existing approved drugs — that modulate host immune responses rather than directly targeting the pathogen. Repurposed therapeutics have been successfully identified for cancer and COVID-19 by finding drugs that reverse disease gene expression patterns (an approach called ‘connectivity scoring’), but this approach remains largely unexplored for bacterial infections like TB. The application of transcriptome-based methods to TB faces significant challenges, including dataset heterogeneity across transcriptomics platforms and biological conditions, uncertainty about optimal scoring methods, and lack of systematic approaches to identify robust disease signatures. Here, we developed an integrative computational workflow combining multiple connectivity scoring methods with consensus disease signature construction and used it to systematically identify FDA-approved drugs as promising TB host-directed therapeutics. Our framework integrates six complementary connectivity methods and constructs weighted consensus signatures from 21 TB gene expression datasets spanning microarray and RNA-seq platforms, diverse cell types, and infection conditions. Our approach prioritized 140 high-confidence drug candidates that consistently reverse TB-associated gene expression changes, successfully recovering known HDTs, including statins (atorvastatin, lovastatin, fluvastatin) and vitamin D receptor agonists (calcitriol). We identified promising novel candidates such as niclosamide and tamoxifen, both recently validated in experimental TB models, and revealed enrichment for therapeutically relevant mechanisms, e.g., cholesterol metabolism inhibition and immune modulation pathways. Network analysis of disease-drug interactions identified 10 key bridging genes (including MYD88, RELA, and CXCR2) that represent potential novel druggable targets for TB host-directed therapy. This work establishes transcriptome-based connectivity mapping as a viable approach for systematic HDT discovery in bacterial infections and provides a robust computational framework applicable to other infectious diseases. Our findings offer immediate opportunities for experimental validation of prioritized drug candidates and mechanistic investigation of identified druggable targets in TB pathogenesis."><link rel=alternate hreflang=en-us href=/publication/drugrep_tb/><meta name=theme-color content="hsl(339, 90%, 68%)"><script src=/js/mathjax-config.js></script>
<link rel=stylesheet href=https://cdnjs.cloudflare.com/ajax/libs/academicons/1.8.6/css/academicons.min.css integrity="sha256-uFVgMKfistnJAfoCUQigIl+JfUaP47GrRKjf6CTPVmw=" crossorigin=anonymous><link rel=stylesheet href=https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.0-1/css/all.min.css integrity="sha256-4w9DunooKSr3MFXHXWyFER38WmPdm361bQS/2KUWZbU=" crossorigin=anonymous><link rel=stylesheet href=https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.css integrity="sha256-Vzbj7sDDS/woiFS3uNKo8eIuni59rjyNGtXfstRzStA=" crossorigin=anonymous><link rel=stylesheet href=https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/styles/github.min.css crossorigin=anonymous title=hl-light disabled><link rel=stylesheet href=https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/styles/dracula.min.css crossorigin=anonymous title=hl-dark><link rel=stylesheet href=https://cdnjs.cloudflare.com/ajax/libs/leaflet/1.5.1/leaflet.css integrity="sha256-SHMGCYmST46SoyGgo4YR/9AlK1vf3ff84Aq9yK4hdqM=" crossorigin=anonymous><script src=https://cdnjs.cloudflare.com/ajax/libs/lazysizes/5.1.2/lazysizes.min.js integrity="sha256-Md1qLToewPeKjfAHU1zyPwOutccPAm5tahnaw7Osw0A=" crossorigin=anonymous async></script>
<script src=https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-chtml.js integrity crossorigin=anonymous async></script>
<link rel=stylesheet href="https://fonts.googleapis.com/css?family=Montserrat:400,700%7CRoboto:400,400italic,700%7CRoboto+Mono&display=swap"><link rel=stylesheet href=/css/academic.css><link rel=manifest href=/index.webmanifest><link rel=icon type=image/png href=/images/icon_hu0b7a4cb9992c9ac0e91bd28ffd38dd00_9727_32x32_fill_lanczos_center_3.png><link rel=apple-touch-icon type=image/png href=/images/icon_hu0b7a4cb9992c9ac0e91bd28ffd38dd00_9727_192x192_fill_lanczos_center_3.png><link rel=canonical href=/publication/drugrep_tb/><meta property="twitter:card" content="summary_large_image"><meta property="twitter:site" content="@JRaviLab"><meta property="twitter:creator" content="@JRaviLab"><meta property="og:site_name" content="JRaviLab"><meta property="og:url" content="/publication/drugrep_tb/"><meta property="og:title" content="Integrative transcriptome-based drug repurposing in tuberculosis | JRaviLab"><meta property="og:description" content="Tuberculosis (TB) remains the second leading cause of infectious disease mortality worldwide, killing over one million people annually. Rising antibiotic resistance has created an urgent need for host-directed therapeutics (HDTs) — preferably by repurposing existing approved drugs — that modulate host immune responses rather than directly targeting the pathogen. Repurposed therapeutics have been successfully identified for cancer and COVID-19 by finding drugs that reverse disease gene expression patterns (an approach called ‘connectivity scoring’), but this approach remains largely unexplored for bacterial infections like TB. The application of transcriptome-based methods to TB faces significant challenges, including dataset heterogeneity across transcriptomics platforms and biological conditions, uncertainty about optimal scoring methods, and lack of systematic approaches to identify robust disease signatures. Here, we developed an integrative computational workflow combining multiple connectivity scoring methods with consensus disease signature construction and used it to systematically identify FDA-approved drugs as promising TB host-directed therapeutics. Our framework integrates six complementary connectivity methods and constructs weighted consensus signatures from 21 TB gene expression datasets spanning microarray and RNA-seq platforms, diverse cell types, and infection conditions. Our approach prioritized 140 high-confidence drug candidates that consistently reverse TB-associated gene expression changes, successfully recovering known HDTs, including statins (atorvastatin, lovastatin, fluvastatin) and vitamin D receptor agonists (calcitriol). We identified promising novel candidates such as niclosamide and tamoxifen, both recently validated in experimental TB models, and revealed enrichment for therapeutically relevant mechanisms, e.g., cholesterol metabolism inhibition and immune modulation pathways. Network analysis of disease-drug interactions identified 10 key bridging genes (including MYD88, RELA, and CXCR2) that represent potential novel druggable targets for TB host-directed therapy. This work establishes transcriptome-based connectivity mapping as a viable approach for systematic HDT discovery in bacterial infections and provides a robust computational framework applicable to other infectious diseases. Our findings offer immediate opportunities for experimental validation of prioritized drug candidates and mechanistic investigation of identified druggable targets in TB pathogenesis."><meta property="og:image" content="/publication/drugrep_tb/featured.png"><meta property="twitter:image" content="/publication/drugrep_tb/featured.png"><meta property="og:locale" content="en-us"><meta property="article:published_time" content="2025-06-02T00:00:00+00:00"><meta property="article:modified_time" content="2025-06-02T00:00:00+00:00"><script type=application/ld+json>{"@context":"https://schema.org","@type":"Article","mainEntityOfPage":{"@type":"WebPage","@id":"/publication/drugrep_tb/"},"headline":"Integrative transcriptome-based drug repurposing in tuberculosis","image":["/publication/drugrep_tb/featured.png"],"datePublished":"2025-06-02T00:00:00Z","dateModified":"2025-06-02T00:00:00Z","author":{"@type":"Person","name":"Kewalin Samart"},"publisher":{"@type":"Organization","name":"JRaviLab","logo":{"@type":"ImageObject","url":"/images/icon_hu0b7a4cb9992c9ac0e91bd28ffd38dd00_9727_192x192_fill_lanczos_center_3.png"}},"description":"Tuberculosis (TB) remains the second leading cause of infectious disease mortality worldwide, killing over one million people annually. Rising antibiotic resistance has created an urgent need for host-directed therapeutics (HDTs) — preferably by repurposing existing approved drugs — that modulate host immune responses rather than directly targeting the pathogen. Repurposed therapeutics have been successfully identified for cancer and COVID-19 by finding drugs that reverse disease gene expression patterns (an approach called ‘connectivity scoring’), but this approach remains largely unexplored for bacterial infections like TB. The application of transcriptome-based methods to TB faces significant challenges, including dataset heterogeneity across transcriptomics platforms and biological conditions, uncertainty about optimal scoring methods, and lack of systematic approaches to identify robust disease signatures. Here, we developed an integrative computational workflow combining multiple connectivity scoring methods with consensus disease signature construction and used it to systematically identify FDA-approved drugs as promising TB host-directed therapeutics. Our framework integrates six complementary connectivity methods and constructs weighted consensus signatures from 21 TB gene expression datasets spanning microarray and RNA-seq platforms, diverse cell types, and infection conditions. Our approach prioritized 140 high-confidence drug candidates that consistently reverse TB-associated gene expression changes, successfully recovering known HDTs, including statins (atorvastatin, lovastatin, fluvastatin) and vitamin D receptor agonists (calcitriol). We identified promising novel candidates such as niclosamide and tamoxifen, both recently validated in experimental TB models, and revealed enrichment for therapeutically relevant mechanisms, e.g., cholesterol metabolism inhibition and immune modulation pathways. Network analysis of disease-drug interactions identified 10 key bridging genes (including MYD88, RELA, and CXCR2) that represent potential novel druggable targets for TB host-directed therapy. This work establishes transcriptome-based connectivity mapping as a viable approach for systematic HDT discovery in bacterial infections and provides a robust computational framework applicable to other infectious diseases. Our findings offer immediate opportunities for experimental validation of prioritized drug candidates and mechanistic investigation of identified druggable targets in TB pathogenesis."}</script><title>Integrative transcriptome-based drug repurposing in tuberculosis | JRaviLab</title></head><body id=top data-spy=scroll data-offset=70 data-target=#TableOfContents class=dark><aside class=search-results id=search><div class=container><section class=search-header><div class="row no-gutters justify-content-between mb-3"><div class=col-6><h1>Search</h1></div><div class="col-6 col-search-close"><a class=js-search href=#><i class="fas fa-times-circle text-muted" aria-hidden=true></i></a></div></div><div id=search-box><input name=q id=search-query placeholder=Search... autocapitalize=off autocomplete=off autocorrect=off spellcheck=false type=search></div></section><section class=section-search-results><div id=search-hits></div></section></div></aside><nav class="navbar navbar-expand-lg navbar-light compensate-for-scrollbar" id=navbar-main><div class=container><div class="d-none d-lg-inline-flex"><a class=navbar-brand href=/>JRaviLab</a></div><button type=button class=navbar-toggler data-toggle=collapse data-target=#navbar-content aria-controls=navbar aria-expanded=false aria-label="Toggle navigation">
<span><i class="fas fa-bars"></i></span></button><div class="navbar-brand-mobile-wrapper d-inline-flex d-lg-none"><a class=navbar-brand href=/>JRaviLab</a></div><div class="navbar-collapse main-menu-item collapse justify-content-start" id=navbar-content><ul class="navbar-nav d-md-inline-flex"><li class=nav-item><a class=nav-link href=/#about_group><span>Home</span></a></li><li class=nav-item><a class=nav-link href=/#interests><span>Interests</span></a></li><li class=nav-item><a class=nav-link href=/#news><span>News</span></a></li><li class=nav-item><a class=nav-link href=/#about><span>Team</span></a></li><li class=nav-item><a class=nav-link href=/#publications><span>Papers</span></a></li><li class=nav-item><a class=nav-link href=/#projects><span>Projects</span></a></li><li class=nav-item><a class=nav-link href=/#talks><span>Talks</span></a></li><li class=nav-item><a class=nav-link href=/#posts><span>Posts</span></a></li><li class=nav-item><a class=nav-link href=/#gallery><span>Photos</span></a></li><li class=nav-item><a class=nav-link href=/#contact><span>Contact</span></a></li></ul></div><ul class="nav-icons navbar-nav flex-row ml-auto d-flex pl-md-2"><li class=nav-item><a class="nav-link js-search" href=#><i class="fas fa-search" aria-hidden=true></i></a></li><li class=nav-item><a class="nav-link js-dark-toggle" href=#><i class="fas fa-moon" aria-hidden=true></i></a></li></ul></div></nav><div class=pub><div class="article-container pt-3"><h1>Integrative transcriptome-based drug repurposing in tuberculosis</h1><div class=article-metadata><div><span><a href=/authors/kewalin-samart/>Kewalin Samart</a></span>, <span><a href=/authors/ling-thang/>Ling Thang</a></span>, <span><a href=/authors/landon-buskirk/>Landon Buskirk</a></span>, <span><a href=/authors/amy-tonielli/>Amy Tonielli</a></span>, <span><a href=/authors/arjun-krishnan/>Arjun Krishnan</a></span>, <span><a href=/authors/admin/>Janani Ravi</a></span></div><span class=article-date>June 2025</span>
<span class=middot-divider></span>
<span class=article-categories><i class="fas fa-folder mr-1"></i><a href=/categories/research/>Research</a></span></div><div class="btn-links mb-3"><a class="btn btn-outline-primary my-1 mr-1" href=https://doi.org/10.1101/2025.06.02.657296 target=_blank rel=noopener>Preprint</a>
<a class="btn btn-outline-primary my-1 mr-1" href=https://www.biorxiv.org/content/10.1101/2025.06.02.657296v1.full.pdf+html target=_blank rel=noopener>PDF</a>
<a class="btn btn-outline-primary my-1 mr-1" href=/project/host-response/>Project</a>
<a class="btn btn-outline-primary my-1 mr-1" href=https://doi.org/10.1101/2025.06.02.657296 target=_blank rel=noopener>DOI</a></div></div><div class="article-header article-container featured-image-wrapper mt-4 mb-4" style=max-width:720px;max-height:413px><div style=position:relative><img src=/publication/drugrep_tb/featured_hu8f5b042a5818dc61a9b5ed51fdef08c7_641906_720x0_resize_lanczos_3.png alt class=featured-image></div></div><div class=article-container><h3>Abstract</h3><p class=pub-abstract>Tuberculosis (TB) remains the second leading cause of infectious disease mortality worldwide, killing over one million people annually. Rising antibiotic resistance has created an urgent need for host-directed therapeutics (HDTs) — preferably by repurposing existing approved drugs — that modulate host immune responses rather than directly targeting the pathogen. Repurposed therapeutics have been successfully identified for cancer and COVID-19 by finding drugs that reverse disease gene expression patterns (an approach called ‘connectivity scoring’), but this approach remains largely unexplored for bacterial infections like TB. The application of transcriptome-based methods to TB faces significant challenges, including dataset heterogeneity across transcriptomics platforms and biological conditions, uncertainty about optimal scoring methods, and lack of systematic approaches to identify robust disease signatures. Here, we developed an integrative computational workflow combining multiple connectivity scoring methods with consensus disease signature construction and used it to systematically identify FDA-approved drugs as promising TB host-directed therapeutics. Our framework integrates six complementary connectivity methods and constructs weighted consensus signatures from 21 TB gene expression datasets spanning microarray and RNA-seq platforms, diverse cell types, and infection conditions. Our approach prioritized 140 high-confidence drug candidates that consistently reverse TB-associated gene expression changes, successfully recovering known HDTs, including statins (atorvastatin, lovastatin, fluvastatin) and vitamin D receptor agonists (calcitriol). We identified promising novel candidates such as niclosamide and tamoxifen, both recently validated in experimental TB models, and revealed enrichment for therapeutically relevant mechanisms, e.g., cholesterol metabolism inhibition and immune modulation pathways. Network analysis of disease-drug interactions identified 10 key bridging genes (including MYD88, RELA, and CXCR2) that represent potential novel druggable targets for TB host-directed therapy. This work establishes transcriptome-based connectivity mapping as a viable approach for systematic HDT discovery in bacterial infections and provides a robust computational framework applicable to other infectious diseases. Our findings offer immediate opportunities for experimental validation of prioritized drug candidates and mechanistic investigation of identified druggable targets in TB pathogenesis.</p><div class=row><div class=col-md-1></div><div class=col-md-10><div class=row><div class="col-12 col-md-3 pub-row-heading">Type</div><div class="col-12 col-md-9"><a href=/publication/#3>Preprint</a></div></div></div><div class=col-md-1></div></div><div class="d-md-none space-below"></div><div class=row><div class=col-md-1></div><div class=col-md-10><div class=row><div class="col-12 col-md-3 pub-row-heading">Publication</div><div class="col-12 col-md-9"><em>bioRxiv</em></div></div></div><div class=col-md-1></div></div><div class="d-md-none space-below"></div><div class=space-below></div><div class=article-style><p>AK and JR are co-corresponding authors.</p></div><div class=article-tags><a class="badge badge-light" href=/tags/host-response/>host-response</a>
<a class="badge badge-light" href=/tags/drug-repurposing/>drug-repurposing</a>
<a class="badge badge-light" href=/tags/disease-signature/>disease-signature</a>
<a class="badge badge-light" href=/tags/compbio-bioinfo/>compbio-bioinfo</a></div><div class="media author-card content-widget-hr"><img class="avatar mr-3 avatar-circle" src=/authors/kewalin-samart/avatar_hu3c30d8d69a34e52af48d253ceeb0e5bb_443178_270x270_fill_q90_lanczos_center.jpg alt=Avatar><div class=media-body><h5 class=card-title><a href=/authors/kewalin-samart/>Kewalin Samart</a></h5><h6 class=card-subtitle>Graduate Researcher</h6><ul class=network-icon aria-hidden=true><li><a href="https://scholar.google.com/citations?hl=en&amp;user=e2QIJJYAAAAJ" target=_blank rel=noopener><i class="ai ai-google-scholar"></i></a></li><li><a href=https://www.linkedin.com/in/kewalinsamart/ target=_blank rel=noopener><i class="fab fa-linkedin"></i></a></li><li><a href=https://github.com/KewalinSamart target=_blank rel=noopener><i class="fab fa-github"></i></a></li><li><a href=https://twitter.com/KewalinSamart target=_blank rel=noopener><i class="fab fa-twitter"></i></a></li><li><a href=https://kewalinsamart.github.io/curriculum-vitae/Kewalin_Samart_CV.pdf target=_blank rel=noopener><i class="ai ai-cv"></i></a></li></ul></div></div><div class="article-widget content-widget-hr"><h3>Related</h3><ul><li><a href=/talk/2021-cu/>Computational approaches to study molecular pathogenesis and intervention of infectious diseases</a></li><li><a href=/publication/connectivity_scores/>Reconciling Multiple Connectivity Scores for Drug Repurposing</a></li><li><a href=/project/host-response/>Host-responses to infection</a></li><li><a href=/project/srna/>sRNA discovery</a></li><li><a href=/joinus/>Join us!</a></li></ul></div></div></div><script src=https://cdnjs.cloudflare.com/ajax/libs/jquery/3.4.1/jquery.min.js integrity="sha256-CSXorXvZcTkaix6Yvo6HppcZGetbYMGWSFlBw8HfCJo=" crossorigin=anonymous></script>
<script src=https://cdnjs.cloudflare.com/ajax/libs/jquery.imagesloaded/4.1.4/imagesloaded.pkgd.min.js integrity="sha256-lqvxZrPLtfffUl2G/e7szqSvPBILGbwmsGE1MKlOi0Q=" crossorigin=anonymous></script>
<script src=https://cdnjs.cloudflare.com/ajax/libs/jquery.isotope/3.0.6/isotope.pkgd.min.js integrity="sha256-CBrpuqrMhXwcLLUd5tvQ4euBHCdh7wGlDfNz8vbu/iI=" crossorigin=anonymous></script>
<script src=https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.js integrity="sha256-yt2kYMy0w8AbtF89WXb2P1rfjcP/HTHLT7097U8Y5b8=" crossorigin=anonymous></script>
<script src=https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/highlight.min.js integrity="sha256-eOgo0OtLL4cdq7RdwRUiGKLX9XsIJ7nGhWEKbohmVAQ=" crossorigin=anonymous></script>
<script src=https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.18.1/languages/r.min.js></script>
<script src=https://cdnjs.cloudflare.com/ajax/libs/leaflet/1.5.1/leaflet.js integrity="sha256-EErZamuLefUnbMBQbsEqu1USa+btR2oIlCpBJbyD4/g=" crossorigin=anonymous></script>
<script>const code_highlighting=!0</script><script>const isSiteThemeDark=!0</script><script>const search_config={indexURI:"/index.json",minLength:1,threshold:.3},i18n={no_results:"No results found",placeholder:"Search...",results:"results found"},content_type={post:"Posts",project:"Projects",publication:"Publications",talk:"Talks"}</script><script id=search-hit-fuse-template type=text/x-template>
      <div class="search-hit" id="summary-{{key}}">
      <div class="search-hit-content">
        <div class="search-hit-name">
          <a href="{{relpermalink}}">{{title}}</a>
          <div class="article-metadata search-hit-type">{{type}}</div>
          <p class="search-hit-description">{{snippet}}</p>
        </div>
      </div>
      </div>
    </script><script src=https://cdnjs.cloudflare.com/ajax/libs/fuse.js/3.2.1/fuse.min.js integrity="sha256-VzgmKYmhsGNNN4Ph1kMW+BjoYJM2jV5i4IlFoeZA9XI=" crossorigin=anonymous></script>
<script src=https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/jquery.mark.min.js integrity="sha256-4HLtjeVgH0eIB3aZ9mLYF6E8oU5chNdjU6p6rrXpl9U=" crossorigin=anonymous></script>
<script src=/js/academic.min.df22e735169cca39ea07a999d8cba15f.js></script><div class=container><footer class=site-footer><p class=powered-by>© Janani Ravi, 2025 &#183;
Powered by the
<a href=https://sourcethemes.com/academic/ target=_blank rel=noopener>Academic theme</a> for
<a href=https://gohugo.io target=_blank rel=noopener>Hugo</a>.
<span class=float-right aria-hidden=true><a href=# class=back-to-top><span class=button_icon><i class="fas fa-chevron-up fa-2x"></i></span></a></span></p></footer></div><div id=modal class="modal fade" role=dialog><div class=modal-dialog><div class=modal-content><div class=modal-header><h5 class=modal-title>Cite</h5><button type=button class=close data-dismiss=modal aria-label=Close>
<span aria-hidden=true>&#215;</span></button></div><div class=modal-body><pre><code class="tex hljs"></code></pre></div><div class=modal-footer><a class="btn btn-outline-primary my-1 js-copy-cite" href=# target=_blank><i class="fas fa-copy"></i> Copy</a>
<a class="btn btn-outline-primary my-1 js-download-cite" href=# target=_blank><i class="fas fa-download"></i> Download</a><div id=modal-error></div></div></div></div></div></body></html>